A high-performance liquid chromatographic method for the measurement of deferoxamine in body fluids.
A high-performance liquid chromatography method for the analysis of deferoxamine (DFO) in 100 microliters of serum or plasma is described. The procedure involves the addition of the internal standard ciprofloxacin to the sample, followed by ultrafiltration to remove protein. The ultrafiltrate is then directly injected into the chromatography system. Separation is achieved using a reverse-phase mu Bondapak C18 column and a ternary solvent system (sodium phosphate:acetonitrile:methanol) running at 2.0 ml/min. Assay time is 10 min, and chromatograms show no interference from coadministered drugs during this period of time. Coefficients of variation were found to be less than 5%, and analytical recovery of DFO was 85%. Validation experiments in an experimental dog model and in patients with iron overload demonstrate that the method is appropriate for studying the pharmacokinetics of DFO in thalassemic patients receiving drug for the treatment of chronic iron overload.
Tesoro
A
A
Division of Clinical Pharmacology, Hospital for Sick Children, Ontario, Canada.
Leeder
J S
JS
Bentur
Y
Y
Klein
J
J
Freedman
M
M
Koren
G
G
D000293:Adolescent; D000818:Animals; D002851:Chromatography, High Pressure Liquid; D002939:Ciprofloxacin / Q000097:blood / Q000652:urine; D003676:Deferoxamine / Q000032:analysis* / Q000097:blood / Q000652:urine; D004285:Dogs; D006801:Humans; D013789:Thalassemia / Q000097:blood / Q000652:urine
D002939:Ciprofloxacin; D003676:Deferoxamine